Alseres Pharmaceuticals (OTCMKTS:ALSE) vs. Traws Pharma (NASDAQ:TRAW) Head-To-Head Analysis

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Traws Pharma (NASDAQ:TRAW) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Traws Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Traws Pharma	$2.79 million	5.17	$9.17 million	($1.69)	-0.84

Traws Pharma has higher revenue and earnings than Alseres Pharmaceuticals.

Analyst Ratings

This is a breakdown of recent ratings for Alseres Pharmaceuticals and Traws Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Traws Pharma	1	1	1	1	2.50

Traws Pharma has a consensus price target of $8.00, suggesting a potential upside of 463.38%. Given Traws Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Alseres Pharmaceuticals.

Insider & Institutional Ownership

8.0% of Traws Pharma shares are held by institutional investors. 8.9% of Alseres Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alseres Pharmaceuticals and Traws Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Traws Pharma	N/A	-913.18%	-133.88%

Summary

Traws Pharma beats Alseres Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Traws Pharma

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.